High dose vitamin D in multiple sclerosis (MS)

Home

Pages

Neurology

Add annotation to this page

Authoring team

A study investigated whether vitamin D reduce disease activity in patients with clinically isolated syndrome (CIS) typical for multiple sclerosis when given at a high dose as monotherapy (1):

randomised clinical trial including 303 patients treated with oral high-dose cholecalciferol or placebo

primary outcome measure of disease activity was defined as occurrence of a relapse and/or magnetic resonance imaging activity (new and/or contrast-enhancing lesions) over 24 months of follow-up

primary outcome was observed in 94 patients (60.3%) in the vitamin D group and 109 patients (74.1%) in the placebo group (hazard ratio, 0.66)

was a statistically significant difference

oral cholecalciferol 100 000 IU every 2 weeks significantly reduced disease activity in CIS and early relapsing-remitting MS

Thouvenot E, Laplaud D, Lebrun-Frenay C, et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. 

Annotations let you add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. Reflective notes let you add information to the CPD dashboard based on the content of this page: what did you learn from it and how might it change your practice?

Annotations let you add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

High dose vitamin D in multiple sclerosis (MS)

Create an account to add page annotations